Crescita Therapeutics (CTX) Q4 2024 earnings summary

Executive summary

• Q4-2024 revenue rose to $6.9M from $4.7M year-over-year, mainly due to manufacturing reimbursement and higher skincare sales, offset by lower licensing royalties.

• Net loss for Q4-2024 was $(162)K, slightly higher than $(150)K in Q4-2023; full-year net loss increased to $(2.75)M from $(1.99)M.

• Expanded product portfolio with Aquafolia acquisition, secured new manufacturing and distribution agreements, and maintained strong cash position of $9.3M.

Financial highlights

• Q4-2024 revenue up $2.2M year-over-year, driven by $1.6M reimbursement and higher skincare sales; offset by $1.3M licensing royalties that did not repeat.

• Gross profit for Q4-2024 was $3.0M (43.4% margin), down from $3.1M (64.8%) due to lower licensing royalties and reimbursement impact.

• Full-year 2024 revenue grew to $19.6M from $17.5M; gross profit fell to $9.6M (49.1% margin) from $10.4M (59.1%).

• Adjusted EBITDA for Q4-2024 was $151K, down from $245K; full-year Adjusted EBITDA was $(1.54)M, down from $(368)K.

• Cash and cash equivalents at year-end were $9.3M, down $112K year-over-year after strategic investments.

Outlook and guidance

• U.S. relaunch of Pliaglis expected in late 2025 under new distribution agreement.

• Management prioritizes cash management and continues to seek opportunities to enhance revenue and profits.